Investors

Corporate Profile

Geron is a clinical stage biopharmaceutical company developing a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. Imetelstat is currently being tested in two clinical trials: IMbark™, a Phase 2 trial in myelofibrosis (MF) and IMerge™, a Phase 2/3 trial in myelodysplastic syndromes (MDS). These clinical trials are being conducted by Janssen Biotech, Inc., under a collaboration and license agreement, in which Janssen were granted the exclusive rights to develop and commercialize imetelstat worldwide for all indications in oncology, including hematologic myeloid malignancies, and all other human therapeutic uses.

Telomerase is an enzyme that enables cancer cells, including malignant progenitor cells, to maintain telomere length, which provides them with the capacity for limitless, uncontrolled proliferation. Using Geron’s proprietary nucleic acid chemistry, imetelstat was designed as an oligonucleotide that targets and binds with high affinity to the active site of telomerase, thereby directly inhibiting telomerase activity and impeding malignant cell proliferation. Early clinical data, including molecular responses in essential thrombocythemia (ET) and remissions, including reversal of bone marrow fibrosis in MF, suggest imetelstat may have disease-modifying activity by inhibiting the progenitor cells of the malignant clones for the underlying diseases.

Recent News

Date Title and Summary  
Toggle Summary Geron Appoints Vice President, Pharmacovigilance and Drug Safety
MENLO PARK, Calif. , Jan. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced the hiring of the first of several key leadership positions as it rebuilds the in-house development team to support its plans to initiate a Phase 3 clinical trial of imetelstat in lower risk
Toggle Summary Geron Announces New Board Leadership Structure
CEO John A. Scarlett Appointed Chairman Karin Eastham Appointed Lead Independent Director MENLO PARK, Calif. , Dec. 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced changes to the leadership structure of the Company’s Board of Directors.
Toggle Summary Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that results from IMbark, a Phase 2 clinical trial of

Upcoming Events

More >>
There are currently no events to display.

Corporate Presentation

Documents

Stock Information

Copyright West LLC. Minimum 15 minutes delayed.

Contact Information

CG Capital
877-889-1972

investor@geron.com